Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2020 Virtual Congress 1000x1000

Watch the webcasts from our industry partners Satellite Symposia

BIOMARKERS/PATHWAYS

The HER-pathway in advanced solid tumours: Advances in targeting HER2 and future prospects for HER3
Medscape

BREAST CANCER

Advancing Knowledge in Early and Metastatic Triple-Negative Breast Cancer
F. Hoffmann-La Roche

HER tomorrow in HER2+ metastatic breast cancer
AstraZeneca

The complete picture: Managing breast cancer in the real-world
Pfizer Oncology

Transforming patient care: Leveraging the latest clinical data in HER2-positive eBC
F. Hoffmann-La Roche

GASTROINTESTINAL TUMOURS

Can current treatment strategies for mCRC be further optimized?
Servier

Current status and future directions for immunotherapy in hepatocellular carcinoma
AstraZeneca

Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
F. Hoffmann-La Roche

Joining efforts beyond first-line management in patients with metastatic pancreatic cancer
Servier

The future is now: Transforming management of GI cancer with immuno-oncology
Bristol Myers Squibb

The today and tomorrow of systemic treatment for HCC
Ipsen

 

GENITOURINARY TUMOURS (NON-PROSTATE)

Harnessing the Potential of the Immune System: Clinical Insights From Utilizing CTLA-4 Within a Dual I-O Approach in aRcc
Bristol Myers Squibb

Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
F. Hoffmann-La Roche

What does the changing treatment landscape for aRCC mean for patient care: An expert discussion
Ipsen

 

GENITOURINARY TUMOURS (PROSTATE)

Advanced prostate cancer: How do we move forward in patient management?
Janssen

Building a new paradigm in prostate cancer
Pfizer Oncology

Extending overall survival in nmCRPC while maintaining quality of life: Can we have it all?
PeerVoice

PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
AstraZeneca

Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
F. Hoffmann-La Roche

 

GYNECOLOGICAL TUMOURS

Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
AstraZeneca

Treatment options for women with advanced ovarian cancer: Evaluating the evidence
GSK

Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
GSK

 

IMMUNO-ONCOLOGY

Antibody Drug Conjugates (ADCs): Advancements in the treatment of solid tumours
Daiichi Sankyo

Current status and future directions for immunotherapy in hepatocellular carcinoma
AstraZeneca

Exploring the Current and Evolving Landscape in Thoracic Cancers
Bristol Myers Squibb

Immune checkpoint blockade in non-melanoma skin cancer
Sanofi Genzyme

Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
F. Hoffmann-La Roche

Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer

F. Hoffmann-La Roche

The future is now: Transforming management of GI cancer with immuno-oncology

Bristol Myers Squibb

Update on the evolving landscape for endometrial cancer treatment with Immunotherapy

GSK

 

LUNG CANCER

Intrinsic and acquired resistance to EGFR TKIs: New therapies on the horizon
Janssen

Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Pfizer Oncology

Treatment Options for Non-Small Cell Lung Cancer
Boehringer Ingelheim

Evolving strategies: Managing treatment of early stage and advanced lung cancers
AstraZeneca

Exploring the Current and Evolving Landscape in Thoracic Cancers
Bristol Myers Squibb

MELANOMA AND OTHER SKIN CANCERS

Immune checkpoint blockade in non-melanoma skin cancer
Sanofi Genzyme

Melanoma in 2020: Reflect, reset, and continue
Bristol Myers Squibb

 

PRECISION MEDICINE

Precision medicine in Real-world clinical practice: Perspectives from a multidisciplinary team
Bayer

Putting personalised healthcare at the heart of clinical practice
F. Hoffmann-La Roche

 

REAL WORLD EVIDENCE / MULTIDISCIPLINARY

Precision medicine in Real-world clinical practice: Perspectives from a multidisciplinary team
Bayer

RWE and me: Multidisciplinary views on real-world evidence (RWE) in oncology
Pfizer Oncology

The complete picture: Managing breast cancer in the real-world
Pfizer Oncology

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings